Skip to main content

previous disabled Page of 2
and
  1. Article

    Open Access

    Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial

    Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yields worse efficacy results, and cause...

    S. B. Patil, M. Tamirat, K. Khazhidinov, E. Ardizzoni, M. Atger, A. Austin in Trials (2023)

  2. Article

    Open Access

    Mesoscopic Klein-Schwinger effect in graphene

    Strong electric field annihilation by particle–antiparticle pair creation, also known as the Schwinger effect, is a non-perturbative prediction of quantum electrodynamics. Its experimental demonstration remain...

    A. Schmitt, P. Vallet, D. Mele, M. Rosticher, T. Taniguchi, K. Watanabe in Nature Physics (2023)

  3. Article

    Open Access

    Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial

    Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. While most MDR/RR-TB patients do not re...

    L. Guglielmetti, E. Ardizzoni, M. Atger, E. Baudin, E. Berikova, M. Bonnet in Trials (2021)

  4. No Access

    Article

    Locally unresectable differentiated thyroid cancer: outcomes and perspectives

    Differentiated thyroid cancer (DTC) patients with an unresectable primary tumor cannot benefit from curative surgery, and radioiodine treatment for locoregional and distant disease is not possible with the thy...

    L. Lamartina, Y. Godbert, C. Nascimento, C. Do Cao, S. Hescot, I. Borget in Endocrine (2020)

  5. No Access

    Article

    Histologically Proven Bronchial Neuroendocrine Tumors in MEN1: A GTE 51-Case Cohort Study

    To evaluate the natural history of MEN1-related bronchial endocrine tumors (br-NETs) and to determine their histological characteristics, survival and causes of death.

    P. Lecomte, C. Binquet, M. Le Bras, A. Tabarin in World Journal of Surgery (2018)

  6. No Access

    Article

    Therapeutic Strategies for Advanced Pancreatic Neuroendocrine Tumors with Segmental Portal Hypertension

    Pancreatic neuroendocrine tumors (PNET) locally advanced may lead to significant local symptoms especially segmental portal hypertension (SPH) with risk of bleeding. The aim of our study was to evaluate the ro...

    F. Dumont, Y. Goudard, C. Caramella, D. Goéré, E. Baudin in World Journal of Surgery (2015)

  7. No Access

    Article

    Screening in asymptomatic SDHx mutation carriers: added value of 18F-FDG PET/CT at initial diagnosis and 1-year follow-up

    Specific recommendations on screening modalities for paraganglioma (PGL) and phaeochromocytoma (PCC) in asymptomatic SDHx mutation carriers (relatives) are still lacking. We evaluated the added value of 18F-FDG P...

    C. Lepoutre-Lussey, C. Caramella, F. Bidault in European Journal of Nuclear Medicine and M… (2015)

  8. No Access

    Article

    Thermal ablation techniques: a curative treatment of bone metastases in selected patients?

    Thermal ablation techniques (radiofrequency-ablation/cryotherapy) can be indicated with a curative intent. The success rate and prognostic factors for complete treatment were analysed.

    F. Deschamps, G. Farouil, N. Ternes, A. Gaudin, A. Hakime in European Radiology (2014)

  9. No Access

    Article

    Caractérisation des tumeurs neuroendocrines digestives ou thoraciques

    Once the diagnosis of a neuroendocrine tumour has been made, characterisation is an essential step before therapy. It comes before the decision regarding treatment is made. This requires a multidisciplinary te...

    E. Baudin, J. -Y. Scoazec, C. Caramella, S. Leboulleux, O. Caron, D. Deandreis in Oncologie (2013)

  10. No Access

    Article

    Efficacia di everolimus in pazienti con insulinoma metastatico ed ipoglicemia refrattaria

    V. Bernard, C. Lombard-Bohas, M. C. Taquet, F. X. Caroli-Bosc in L’Endocrinologo (2013)

  11. No Access

    Article

    Patologia surrenalica nella MEN-1. Analisi di 715 casi dal database “Groupe d’étude des tumeurs endocrines”

    B. Gatta-Cherifi, O. Chabre, A. Murat, P. Niccoli, C. Cardot-Bauters in L’Endocrinologo (2012)

  12. Article

    Therapeutic Management of Advanced Adrenocortical Carcinoma: What Do We Know in 2011?

    The prognosis of advanced adrenocortical carcinoma (ACC) is dismal but heterogeneous. In 2011, mitotane is the only drug approved in Europe and US for the treatment of advanced ACC. Mitotane exerts both antise...

    E. Baudin, S. Leboulleux, A. Al Ghuzlan, C. Chougnet, J. Young in Hormones and Cancer (2011)

  13. No Access

    Article

    La positività della 18FDG-PET/TC a carico della ghiandola surrenalica controlaterale in pazienti surrenectomizzati per carcinoma surrenalico non è marker di malignità

    S. Leboulleux, D. Deandreis, C. Escorrou, A. Al Ghuzlan, F. Bidault in L’Endocrinologo (2011)

  14. No Access

    Article

    Endocrine pancreatic tumours: which are the most useful MRI sequences?

    To determine magnetic resonance imaging (MRI) signal and enhancement characteristics of endocrine pancreatic tumours (ETPs) and which MR sequences show them most consistently.

    C. Caramella, C Dromain, T. De Baere, B. Boulet, M. Schlumberger in European Radiology (2010)

  15. No Access

    Chapter

    Localisation gastro-intestinale

    Les tumeurs neuro-endocrines (TE) sont définies par l’expression de protéines de structure des granules et vésicules de sécrétion: la chromogranine A et la synaptophysine. Cette définition commun...

    E. Baudin, D. Elias, C. Dromain, T. De Baere, M. Ducreux in Tumeurs malignes rares (2010)

  16. No Access

    Article

    Motesanib difosfato nel cancro tiroideo differenziato progressivo

    PREMESSE: L’espressione del vascular endothelial growth factor (VEGF) è tipica dei carcinomi tiroidei differenziati ed è associata ad un comportamento aggressivo e ad una evoluzione sfavorevole. Il motesanib difo...

    S. I. Sherman, L. J. Wirth, J. P. Droz, M. Hofmann, L. Bastholt in L’Endocrinologo (2008)

  17. No Access

    Article

    Le cancer de la surrénale. Comment optimiser la prise en charge d’un cancer rare? UPC Inca, COMETE

    Adrenal cancers (adrenal cortical carcinoma, malignant pheochromocytoma and paraganglioma) are rare tumours that may occur as a familial disease. Medical treatments did not show any efficiency in the managemen...

    X. Bertagna, R. Libé, P. -F. Plouin, E. Baudin in Oncologie (2008)

  18. No Access

    Chapter

    Tumeurs endocrines gastro-entéro-pancréatiques (TE GEP): facteurs pronostiques

    Ce chapitre fait le point sur les facteurs pronostiques des tumeurs endocrines gastro-entéro-pancréatiques (TE GEP) non à petites cellules (1, 2). Nous utiliserons le terme de « tumeur endocrine », pour définir d...

    É. Baudin, D. Malka, J. Guigay, M. Ducreux in Tumeurs endocrines thoraciques et digestives (2008)

  19. No Access

    Chapter

    Chimiothérapie des tumeurs endocrines

    Le rôle des traitements médicaux dans la prise en charge des tumeurs endocrines digestives et pancréatiques (TE) est double : il s’agit d’obtenir un contrôle tumoral et un contrôle des sécrétions hormonales. E...

    M. Ducreux, É. Baudin, C. Lombard-Bohas in Tumeurs endocrines thoraciques et digestives (2008)

  20. No Access

    Chapter

    Tumeurs endocrines gastro-entéro-pancréatiques (TE GEP). Classifications, présentations cliniques, marqueurs biologiques

    Ce chapitre fait le point sur les classifications, les modalités du diagnostic clinique, le bilan biologique des tumeurs endocrines gastro-entéro-pancréatiques (TE GEP) non à petites cellules (1–5). Nous utili...

    É. Baudin, M. Ducreux, M. d’Herbomez in Tumeurs endocrines thoraciques et digestives (2008)

previous disabled Page of 2